Abstract  Caspase-8 is a key player in extrinsic apoptosis and its activity is often downregulated in cancer. However, human Caspase-8 expression is retained in some tumors, including glioblastoma (GBM), suggesting that it may support cancer growth in these contexts. GBM, the most aggressive of the gliomas, is characterized by extensive angiogenesis and by an inflammatory microenvironment that support its development and resistance to therapies. We have recently shown that Caspase-8 sustains neoplastic transformation in vitro in human GBM cell lines. Here, we demonstrate that Caspase-8, through activation of NF-kB, enhances the expression and secretion of VEGF, IL-6, IL-8, IL-1beta and MCP-1, leading to neovascularization and increased resistance to Temozolomide. Importantly, the bioinformatics analysis of microarray gene expression data derived from a set of high-grade human gliomas, shows that high Caspase-8 expression levels correlate with a worse prognosis.

DOI: 10.7554/eLife.22593.001

Introduction

The downregulation of apoptotic pathways is a hallmark of cancer (Hanahan and Weinberg, 2011). Caspase-8 is a central player in the apoptotic cascade triggered by death receptors stimulation (Juo et al., 1998); consistently, its expression (Pingoud-Meier et al., 2003) or its apoptotic activity (Cursi et al., 2006; Safa et al., 2008) are often reduced in cancer. The observation that Caspase-8 is retained in many tumors (reviewed in [Stupack, 2013]) suggests a dual role for Caspase-8 in cancer. The identification of several non-canonical functions of Caspase-8 that are independent of its enzymatic activity and of apoptosis, supports this idea. Indeed, Caspase-8 modulates cell...
Adhesion and migration, suggesting that in cancer cells Caspase-8 may be rewired from apoptosis to alternative pathways that sustain tumor growth (reviewed in [Graf et al., 2014]).

We recently demonstrated that Caspase-8 promotes the proliferation and neoplastic transformation of glioblastoma (GBM) cell lines ([Fianco et al., 2016]). Interestingly, large-scale gene expression approaches have demonstrated Caspase-8 upregulation in GBM compared to normal tissue; in particular, the mesenchymal subtype of GBMs is characterized by high Caspase-8 expression ([Verhaak et al., 2010]).

The fatal nature of GBM is strongly associated with its extensive angiogenesis ([Kargiotis et al., 2006]), and with its capacity to infiltrate throughout the brain tissue and to resist to chemotherapy ([Dunn et al., 2012]).

Tumor neoangiogenesis is strongly supported by an inflammatory microenvironment that also promotes the proliferation of tumor cells and the survival of malignant cells and alters responses to chemotherapeutic agents ([Mantovani et al., 2008]). Consistently, in vitro and in vivo studies have identified high levels of IL-8, IL-6 and IL-1beta in the conditioned media (CM) of several GBM cell lines and in microenvironment of clinical samples (reviewed in [Yeung et al., 2013]). This often depends on overactive EGFR signalling, which stimulates NF-kB, AP-1 and cEBP transcription factors, thereby promoting the expression of IL-8 and IL-6 ([Bonavia et al., 2012; Inda et al., 2010]).

The work of several laboratories has identified Caspase-8 as an activator of NF-kB downstream of antigen receptors ([Su et al., 2005]) and Toll-like receptors ([Lemmers et al., 2007]), as well as in T cells ([Bidère et al., 2006]). These observations, along with the pivotal role of NF-kB in...
modulating cytokine production, in shaping tumor microenvironment and in promoting angiogenesis and GBM progression (reviewed in Karin et al. [2002], Dunn et al. [2012], Yeung et al. [2013] and Nogueira et al. [2011]), prompted us to investigate whether high Caspase-8 expression in GBM promotes these functions.

Results and discussion

To investigate the possible role of Caspase-8 in GBM angiogenesis, we sub-cutaneously injected mice with matrigel-containing conditioned media (CM) from U87MG (U87) cells, in which Caspase-8 expression was genetically silenced (shC8) or not (shcontrol, named CTR) (as shown in Figure 1—figure supplement 1). Matrigel plugs containing CM from U87CTR induced a strong angiogenic response as evidenced by macroscopic analysis and haemoglobin content, similar to that detected in the positive control where VEGF has been added to the media. Importantly, matrigel plugs containing CM from U87 shC8 displayed a significant reduction of both angiogenesis in vivo and the haemoglobin content (Figure 1A and B).

In agreement with this finding, CM from U87shC8 cells was 2.5-fold less potent in triggering the proliferation of Human Umbilical Vein Endothelial Cells (HUVECs) compared to CM from U87CTR cells (Figure 1—figure supplement 2). Moreover, when exposed to CM from U87CTR cells, HUVECs formed tube-like structures resembling a capillary plexus; conversely, partially organized and rounded endothelial cells were observed after the addition of CM from U87shC8 cells (Figure 1—figure supplement 2).

To uncover whether Caspase-8 dependent regulation of angiogenesis correlates with the modulation of tumor growth in vivo, we compared the tumorigenic potential of U87 cells in which the expression of Caspase-8 was genetically inhibited or not. As reported in Figure 1C, after three weeks, U87 cells formed tumors of an average volume of ~1,254 mm³ in all injected mice, whereas U87shC8 cells exhibited a drastically reduced capacity to form tumors (mean tumor volume: ~148 mm³), which were detected in only 29% of injected mice. After 6 weeks, the mean tumor volume generated by U87sh8 cells was ~344 mm³ and tumors were identified in 67% of injected mice (Figure 1C).

In order to evaluate whether the decreased tumor growth observed in shC8 mice compared to CTR was associated with a lower vascular density, we evaluated neovascularization in CTR and shC8 tumors. Tumor vessels were visualized using anti-CD31 mAb, which permitted an assessment of the vascular density of the tumors. Figure 1D shows that there was a significant difference in vascularization between CTR and shC8 tumors; the mean number of vessels per mm² field was 20.52 (±0.62) for CTR and 1.21 (±0.41) for shC8 (p=0.001).

Overall, these data suggest that Caspase-8 expression in GBM is required for tumor growth, maximal proliferation of GBM-associated endothelial cells and angiogenesis, probably through the production of secreted factors.

To measure whether Caspase-8 expression affects the profile of secreted cytokines and growth factors, we used LUMINEX multiplex bead assay, which allows the simultaneous quantification of several cytokines from the same sample (Khalifian et al., 2015). High levels of IL-1β, IL-6, IL-8, MCP-1, VEGF-A and TNFα were present in the CM of U87CTR, as is consistent with previous reports (Albulescu et al., 2013), and the genetic inhibition of Caspase-8 caused a strong decrease in the levels of these cytokines (except TNF alpha) in the CM (Figure 2A). Accordingly, we observed a dramatic reduction of the respective mRNAs upon Caspase-8 downregulation (Figure 2B). We obtained similar results in U87 cells where Caspase-8 expression was inhibited using a different interfering sequence (Figure 2—figure supplement 1), as well as in U251, another GBM cell line (Figure 2—figure supplement 1).

To clarify the significance of our findings, we interrogated mRNA levels in a RNA-seq data set derived from 174 human GBM patients, which is available in Cancer Genome Atlas (TCGA). For each gene, we built a profile of normalized expression data from the 174 samples, and we then compared these profiles using the Pearson product-moment correlation coefficient. Interestingly, the Caspase-8 expression profile positively correlated with those of IL-6, IL-8, IL1β and MCP-1 (Figure 2C and Figure 2—source data 4), ranging from 0.25 when comparing the Caspase-8 and IL-6 GBM expression profiles, to 0.53 for Caspase-8 and MCP-1. All of these correlations were statistically significant.
Figure 1. Caspase-8 expression promotes tumor growth and neoangiogenesis in vitro and in vivo. (A, B) Caspase-8 expression promotes the ability of conditioned medium (CM) from U87 cells to induce neo-angiogenesis in vivo. Representative images illustrate the macroscopic analysis (A) and quantification of Hb content (B) of Matrigel plugs containing CM from Sh Control (CTR, n = 23) or Sh Caspase-8 (shC8, n = 21) cells. The negative (Neg, n = 14) and positive (Pos, n = 20) controls contained heparin alone or heparin plus VEGF, respectively. The values of biological replicates (n) for each
condition are shown as single dot, and are expressed as optical density (OD 540 nm)/g of the Matrigel plug. The Mann-Whitney test (independent samples) was used for statistical analyses. In all experiments, the volume of CM from different samples was normalized on the number of cells for each sample counted when CM was collected. (C) Comparison of the tumor size between U87 CTR and U87/shC8 mouse xenografts. Quantitative analysis, by Kruskal-Wallis test with Bonferroni correction, of the volume of tumors measured at 3 and 6 weeks after cell injection. Each plot graphically shows the central location and scatter/dispersion of the values of each group: the line series in the rectangular-shaped boxes indicate the median value of the data and the end of the vertical lines indicate the minimum and the maximum data value. The means and their confidence intervals are shown in the diamond-shaped box. P-value was calculated according to the independent samples t-test. Each dot corresponds to the tumor value of one mouse. **p<0.001. (D) The microvessel density, determined immunohistochemically by the means of an anti-CD31 antibody recognizing murine endothelial cells, evidenced the presence of a significantly higher number of vessels in CTR cells (evaluated as mean ± SD in CTR tumors) than in shC8 tumors (***p<0.001). Original magnification 40X, scale bar 50 μm.

DOI: 10.7554/eLife.22593.003

The following source data and figure supplements are available for figure 1:

Source data 1. Caspase-8 mRNA is efficiently silenced in shC8 and shC8#2 cell lines compared to CTR cells.
DOI: 10.7554/eLife.22593.004

Source data 2. Caspase-8 expression promotes the ability of conditioned medium (CM) from U87 cells to induce neo-angiogenesis
DOI: 10.7554/eLife.22593.005

Source data 3. Caspase-8 expression promotes tumor growth in mouse xenograft experiments.
DOI: 10.7554/eLife.22593.006

Source data 4. Caspase-8 expression promotes neovascularization in vivo.
DOI: 10.7554/eLife.22593.007

Figure supplement 1. Caspase-8 mRNA and protein expression is efficiently silenced in shC8 and shC8#2 cell lines compared to CTR cells.
DOI: 10.7554/eLife.22593.008

Figure supplement 2. Caspase-8 expression promotes the ability of conditioned medium from U87 cells to induce endothelial cells proliferation and Capillary Tube-Like Network Formation.
DOI: 10.7554/eLife.22593.009

(P-value < 0.0008 for each comparison), whereas there was no significant relationship between the Caspase-8 and VEGF expression profiles (Pearson correlation coefficient 0.09, p-value 0.22).

Overall these results identified a novel role of Caspase-8 in promoting neangiogenesis. This is in agreement with previous studies on Caspase-8 null mice, which showed defects in the angiogenesis programme during development (Scharner et al., 2009).

The expression of the aforementioned cytokines is finely tuned by several transcription factors, among which is NF-kB. In gliomas, NF-kB is often constitutively activated (Cahill et al., 2016), NF-kB-regulated genes are induced (Bonavia et al., 2012), and the expression of these genes correlates inversely with patient prognosis (Nogueira et al., 2011). Consistently, the overexpression of a dominant negative mutant of IKBalpha (IKBaphaS32A/S36A, named IKBapha SR) that inhibits NF-kB signalling severely decreased the expression of IL-6, IL-8, IL1β, MCP-1 and VEGF-A mRNAs in U87 cells (Figure 2—figure supplement 2). Silencing of Caspase-8 in U87 cells did not reduce the amount of NF-kB but strongly decreased its nuclear localization (Figure 3A and B). Similar results were also obtained in U251 GBM cells (Figure 3C). Preliminary immunohistochemistry analysis in formalin-fixed paraffin-embedded tissues suggests a different distribution of NF-kB in CTR (nuclear and cytoplasmic) and in shC8 (mainly cytoplasmic) tumors (Figure 3—figure supplement 1). Consistently, we could detect a significant reduction of VEGF and IL-8 mRNA levels in shC8-derived tumor samples (Figure 3—figure supplement 1). Our results provide the first evidence that Caspase-8 promotes NF-kB activity in GBM in vitro and in vivo. Interestingly, cancer-associated missense mutations of Caspase-8 resulting in stronger activation of NF-kB have been identified recently in head and neck squamous cell carcinoma (Ando et al., 2013).

Having demonstrated that Caspase-8 expression promotes neoplastic transformation in vitro (Fiano et al., 2016) and sustains tumor growth and its microenvironment (Figures 1, 2 and 3), we asked whether Caspase-8 expression affects GBM cells response to therapy. For several decades, the typical treatment for GBM has been radiotherapy; more recently, Temozolomide (TMZ) has been incorporated into the standard treatment as an essential component (Stupp et al., 2005).

As shown in Figure 4A and in Figure 4—figure supplement 1, the down-regulation of Caspase-8 expression significantly sensitized U87 cells to the cytotoxic effects of TMZ. Interestingly, the expression of the dominant negative mutant of IKBalpha, IKBaphaSR, had a similar effect...
Figure 2. Caspase-8 promotes the expression and secretion of cytokines and growth factors. (A) Concentrations (pg/ml) of IL-1β, IL-6, IL-8, MCP-1 (CCL-2), VEGF-A and TNF-α were measured by Luminex assay, in the supernatants of U87 cells upon stable genetic silencing of Caspase-8 expression (Sh C8) or not (ShCTR, named CTR). Data were plotted as mean ± SD and statistical significance was estimated by Unpaired T-test, ***p<0.001. Error bars represent a SD between three independent experiments, each of them performed in technical duplicate. In all experiments, the volume of CM
from different samples was normalized on the number of cells for each sample counted when CM was collected. (B) Quantitative real time RT-PCR on U87CTR cells and U87shC8 cells. Relative quantities were calculated normalizing for TBP. Representative results of a single experiment with n = 3 biological replicates, each one performed in technical duplicate, are shown as mean ± SD (**p-value<0.001). Three independent experiments were consistent. (C) Correlation between Caspase-8 and IL-6, IL-8, IL1β, MCP-1 and VEGF expression in human glioblastoma. Pearson correlation coefficients computed between gene expression profiles for CASP-8, IL-6, IL-8, IL1β, MCP-1 and VEGF, in 174 glioblastoma RNA-Seq samples retrieved from the Cancer Genome Atlas. The correlation coefficient between expression profiles is proportional to the circle radii in the matrix, and additionally color-coded using the color scale reported to the right of the matrix. The plot was generated using the corrplot/ R package (https://cran.r-project.org/web/packages/corrplot).

The following source data and figure supplements are available for figure 2:

**Source data 1.** Caspase-8 promotes the secretion of cytokines and growth factors.

DOI: 10.7554/eLife.22593.011

**Source data 2.** Caspase-8 promotes mRNA expression of cytokines and growth factors.

DOI: 10.7554/eLife.22593.012

**Source data 3.** Data collection for the analysis of the correlation between Caspase-8 and IL-6, IL-8, IL1β, MCP-1 and VEGF expression in human glioblastoma, Figure 2C.

DOI: 10.7554/eLife.22593.013

**Source data 4.** Correlation between Caspase-8 and IL-6, IL-8, IL1β, MCP-1 and VEGF expression in human glioblastoma.

DOI: 10.7554/eLife.22593.014

**Figure supplement 1.** Silencing of Caspase-8 triggers the downregulation of IL-6, IL-8 and VEGF mRNA expression.

DOI: 10.7554/eLife.22593.015

**Figure supplement 2.** Ectopic expression of a dominant negative IKBα triggers the downregulation of IL-6, IL-8, IL1β, MCP-1 and VEGF mRNA expression.

DOI: 10.7554/eLife.22593.016

(Figure 4B), suggesting that Caspase-8 exerts its function via NF-kB signalling, possibly through secreted cytokines. Indeed, as shown in Figure 4C, CM of control cells that endogenously express Caspase-8 was sufficient to restore resistance to TMZ in cells silenced for Caspase-8. Importantly, CM from IKBαSR-expressing cells, like that from Caspase-8-deficient cells, lost such a protective capability (Figure 4D). These results support the conclusion that Caspase-8 expression in GBM cells triggers resistance to TMZ via an autocrine loop and suggest that the level of Caspase-8 expression may correlate with prognosis. To test this hypothesis, we analyzed the survival of 77 high-glioma patients (of which 15 were censored), whose gene expression was measured using microarrays (Phillips et al., 2006). We classified the patients on their Caspase-8 expression, dividing the Caspase-8 expression distribution into three quantiles and considering the first quantile as low expression and the last quantile as high expression. Analysis of the survival curves shows that patients that have higher Caspase-8 expression levels have a lower survival chance than those with lower expression (Chi-squared 10.5 on 1 degree of freedom, p-value 0.00117), supporting our hypothesis (Figure 4E). In addition, we investigated the survival rates of the same 77 patients classified into three distinct subtypes: mesenchymal (23 cases), proneural (30 cases) and proliferative (24 cases) tumors. Patients belonging to each subtype were stratified in terms of high and low Caspase-8 expression, based on the distribution of Caspase-8 probe intensities specific for each subtype. The significantly different Caspase-8 expression levels in the proneural, mesenchymal and proliferative GBMs justified the use of different thresholds for each subtype. For patients classified as proneural, those having high Caspase-8 expression show significantly lower survival probability (Chi-squared 7.2 on 1 degree of freedom, p-value 0.00732), while no difference was observed for the mesenchymal and proliferative subtypes (Figure 4—figure supplement 2).

Overall, we identify a novel function of Caspase-8 (Figure 4F), which supports a double agent role of Caspase-8 in cancer. The classical role of Caspase-8 in apoptosis may account for the correlation between loss of Caspase-8 expression and unfavourable prognosis in medulloblastoma (Pingooud-Meier et al., 2003). Conversely, tumors that are strongly dependent on NFkB activity and cytokine production, such as GBM, may have a selective advantage in retaining Caspase-8 expression. In these contexts, targeting of Caspase-8 expression or of its tumorigenic functions represents a novel therapeutic approach.
**Figure 3.** Caspase-8 expression promotes NFkB translocation into the nucleus. (A) Immunostaining α-p65-NFkB in U87 Sh Caspase-8 and control cell lines. Bar scale: 25 μm. The bar chart represents the cytoplasmic (cyt)/nuclear (nuc) ratio of cell fluorescence intensity (FI) obtained using the Image J program. **p-value<0.001. (B, C) Western blot analysis of fractionated cell lysates of U87 (B) and U251 (C) cell lines.

DOI: 10.7554/eLife.22593.017

Figure 3 continued on next page
Materials and methods

Cell cultures
Caspase-8 was stably genetically silenced in U87 (originally obtained by ATCC) and U251 cell lines as previously described (Fianco et al., 2016). All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum and were routinely tested negative for mycoplasma contamination. Following thawing, cells were used for no longer than one month.

Human umbilical endothelial cells (HUVEC; PromoCell GmbH, Heidelberg, Germany) were cultured as previously reported (Gabellini et al., 2013).

The sequences of Caspase-8 used for interference are: shC8 5’-ATCACAGACTTTGGACAAA-3’, shC8#2 5’-GCCTGGATGTTATTCCAG-3’; the sequence used as control, shcontrol (CTR), is: 5’-GGA TATCCCTCTAGATTA-3’.

The pMIGIKBalphaS32A/S36A (IKBalpha SR) construct was kindly provided by Y. Ciribilli and A. Inga (Brockman et al., 1995; Bisio et al., 2014).

Antibodies and other reagents
Anti Caspase 8 (MBL 1:1000) RRID:AB_590760; anti Tubulin (Sigma-Aldrich 1:2000) RRID:AB_10013740; anti NF-kB (p65) (Santa Cruz 1:1000) RRID:AB_632037; anti SP1 (Santa Cruz 1:1000) RRID:AB_2171050; anti rat mAb CD31 (clone SZ31, Dianova GmbH 1:10) RRID:AB_2631039; anti-NF-kB p65 (clone E379, abcam, 1:1000) RRID:AB_776751; TMZ: temozolomide.

In vitro and in vivo angiogenesis assays
All procedures involving animals and their care were authorized and certified by the decree n.26/2014 of the Italian Minister of Health following the relative guide lines.

For in vivo Matrigel assays, 60 μl 10× concentrated CM from the different cell lines, obtained using Centricon-3 concentrators (Merck Millipore, Billerica, MA) were mixed with 600 μl of Matrigel (BD Bioscience, San Jose, CA), supplemented with heparin (19.2 U; Schwarz Pharma SpA, Milan, Italy). This medium was injected subcutaneously into the flank of 8-week-old C57BL/6 mice (provided by the Animal Care Unit of the Regina Elena Cancer Institute, Rome, Italy). The negative and positive controls contained heparin alone or heparin plus VEGF (60 ng/mice; R&D Systems, Minneapolis, MN), respectively. After 5 days, the angiogenic response was evaluated by macroscopic analysis at autopsy, and by measurement of the hemoglobin (Hb) content in the pellet of matrigel as previously reported (Gabellini et al., 2013). The values were expressed as optical density (OD) at 540 nm/100 mg of matrigel. Each group consisted of ten animals. The experiments were repeated three times.

In vitro HUVEC cell proliferation was evaluated by a colorimetric assay at the end of treatment as described previously (Gabellini et al., 2013). Endothelial capillary tube-like network formation was assessed using Matrigel as described previously (Gabellini et al., 2013). Briefly, 24-well microtiter plates were coated with 300 μl/well unpolymerized matrigel (10 mg/ml) and allowed to polymerize at 37°C. Endothelial cells were plated (5 × 10⁴ cells/well) in 1 ml of serum free medium (negative control), complete medium (positive control), or conditioned medium (CM) obtained from sh control (CTR) or sh Caspase 8 (shC8) cells. After 8 hr, cell growth was observed through a reverted, phase-contrast photomicroscope and photographed. Experiments were repeated at least three times, and each sample was tested in triplicate. Angiogenic activity was quantified by measuring the cumulative length of the sprouts using digital imaging software (Image J) to analyze ten fields per experimental group and experiment.

Fianco et al. eLife 2017;6:e22593. DOI: 10.7554/eLife.22593
Figure 4. Downregulation of Caspase-8 increases sensibility to Temozolomide (TMZ). (A, B) Viability assay represented in the histogram as mean ± SD. U87/CTR control cell lines, U87/shCaspase-8 and U87 IKBalphaSR, were incubated in the presence of Temozolomide (TMZ 0.5 mM for 72 hr) or not. The viability of TMZ-treated cells was assessed with the CellTiter 96 Aqueous One Solution Cell proliferation assay, and was represented as the percentage of inhibition of viability measured in cells without TMZ treatment. Data are represented in the histogram as mean ± SD. Error bars represent

Fianco et al. eLife 2017;6:e22593. DOI: 10.7554/eLife.22593

Figure 4 continued on next page
Luminex assay
Concentrations of IL1-β, IL-6, IL-8, MCP-1 and VEGF-A were simultaneously determined in supernatants of shCtr (CTR) and ShC8 cells (n = 3 biological replicates per group and two technical duplicates for each sample) using a custom-made human magnetic Luminex assay kit (E-Bioscience). The assay procedure was performed according to the manufacturer’s instructions and the plate was read on a Luminex-200 instrument (Luminex Corp., Austin, TX). Data were calculated by generating a calibration curve using the recombinant cytokines specified above, diluted in the cell culture medium used for culturing cells. Concentrations of each analyte were calculated using a standard 5P-logistic weighted curve generated for each target and expressed as picograms per milliliter (pg/ml). Due to out of range readings of undiluted samples, IL-8 concentrations were calculated on 1:10 diluted supernatants. Data were presented as the mean ± SD and the statistical analysis was performed using unpaired T-tests.

Immunofluorescence
Cells were plated on coverslips and maintained at 37°C and 5% CO₂ for 24 hr before staining. Cells were treated or not with TNFα (20 ng/ml) 20 min before staining. Cells were washed with 1x phosphate buffer saline (PBS) three times. They were fixed in 4% paraformaldehyde for 15 min, permeabilized in 0.3% triton x100 for 15 min, blocked with 1% BSA for 1 hr at room temperature, and incubated with primary antibody overnight at 4°C. Secondary antibodies were applied for 1 hr at room temperature, stained with Hoechst for 5 min. The primary antibody used was anti NFkB p65 Santa Cruz (clone C20) 1:200. The secondary antibody was donkey anti rabbit 488 (Jackson Immune Research) 1:200. Images of immunostaining cells were obtained by microscopy using an Olympus BX53 microscope. Quantitative fluorescence data were exported from ImageJ generated histograms into Microsoft Excel software for further analysis and presentation. Cytoplasmic and nuclear staining intensities were compared to give the cytoplasmic/nuclear ratio.

Reverse transcription and real time RT-PCR analyses
One microgram of total RNA isolated by TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) was retrotranscribed with MLV-Reverse Transcriptase (Promega, Madison, WI, USA) according to standard procedures. Ten nanograms of cDNA were employed to quantify the transcripts by real time RT-PCR.
using SYBR Select Master Mix (Applied Biosystem Foster City, CA, USA) and gene-specific primers, which are listed in supplemental information. Real-time PCR was performed using the 7900HT Fast Real-Time PCR System (Applied Biosystem). Relative quantity (RQ) was calculated normalizing for TBP and using a U87CTR sample as calibrator. Mean values and standard deviations of RQ were generated from three biological replicates. Each experiment was performed for two technical replicates.

The following primer sequences were used:

| Primer sequences list | Primer sequence |
|-----------------------|-----------------|
| IL-6-FW | 5'-CAGGAGCCCAAGCTATGAAC -3' |
| IL-6-REV | 5'-GAAGGCAGGCAACAC- 3' |
| IL-8-FW | 5'-GGTGCAATTGGCCAAAGGAG-3' |
| IL-8-RV | 5'-GGGCAGCaAAGGGTTCAGG-3' |
| VEGF-FW | 5'-CCTTGCGTCCTACCTCCAC-3' |
| VEGF-RV | 5'-CCACTCGTAGATGTCGC-3' |
| CCL2-MCP1-FW | 5'-CTTCACTTTCCAAGGGCTG-3' |
| CCL2-MCP1-RV | 5'-GCTTCTTTGGGACACTTGCTG-3' |
| TNFA-FW | 5'-GGGACCTCTCCTCTCAGGAGC-3' |
| TNFA-RV | 5'-TCAGCTTGAGGGTTGTGCAG-3' |
| TBP-FW | 5'-GGCCCGAGAAGCGGGCATATAC-3' |
| TBP-RV | 5'-GGGCCGGAGAAGCGGGCATATAC-3' |
| CASP8-FW | 5'-CAGCAGCCTGGAAGGAGGT -3' |
| CASP8-RV | 5'-CGAGATTGTCATTCCCACACA-3' |

**Protein extracts and immunoblotting analysis**

Cell extracts were prepared in IP buffer (50 mM Tris–HCl [pH 7.5], 250 mM NaCl, 1% NP-40, 5 mM EDTA, 5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 25 mM NaF, 1 mM sodium orthovanadate, 10 μg/ml TPCK, 5 μg/ml TLCK, 1 μg/ml leupeptin, 10 μg/ml soybean trypsin inhibitor, 1 μg/ml apro tinin). For nuclei/cytoplasm cell fractionation, cells were in hypotonic buffer (10 mM HEPES [pH 7.5], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and protease and phosphatase inhibitors at concentrations described below) and incubated for 15 min on ice. NP-40 (0.6% final concentration) was added, and nuclei were harvested by centrifugation at 12,000 g at 4°C for 30 s. The cytoplasmic fraction was recovered, and nuclear proteins were extracted from the pellet in nucleus buffer (20 mM HEPES [pH 7.5], 0.4M NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and protease and phosphatase inhibitors at concentrations described below) for 1 hr at 4°C on a rotating wheel. For immunoblotting, 50–100 μg of proteins were separated by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), blotted onto nitrocellulose membrane, and detected with specific antibodies.

**Cell viability analysis**

U87 cell lines (U87 CTR and U87 Sh Caspase 8) were seeded in 96-well plates (1,000 cells/well) and treated for 72 hr with TMZ 0.5 mM or DMSO as control. Cell viability was analysed by CellTiter 96 Aqueous One Solution Cell proliferation assay (Promega) as previously described (Stagni et al., 2015).

**In vivo tumorigenic assay and angiogenesis analysis**

For in vivo tumorigenicity, female CD-1 nude (nu/nu) mice, at 6–8 weeks old and 22–24 g in body weight, were purchased from Charles River Laboratories (Calco, Italy). 4 × 10^6 U87CTR and U87ShC8 cells were injected subcutaneously into the flank of these mice (24 for each group). Two different experiments (the first one with 8 and the second one with 16 animals for each group) were performed. The mice were observed daily, and their tumor volume (mm^3) was calculated as length ×
width 2 × π/6. The animals were sacrificed 3 (CTR) and 6 (shC8) weeks after cell injection. The results were analysed by pooling together the two experiments to evaluate tumor growth at three weeks (CTR and shC8) and at six weeks (shC8). The three groups were compared using the Kruskal-Wallis test with Bonferroni correction. Immediately after sacrifice, the tumors were removed: half of each tumor was frozen in Trizol and stored at −80°C and the remaining half was fixed in 4% buffered formalin and paraffin embedded for immunohistochemical analysis.

Microvessel density and NFκB expression were evaluated on tumor xenograft paraffin-embedded sections by staining endothelial cells using a CD31 anti rat mAb and the rabbit mAb anti-NF-κB, respectively. Immunoreactions were revealed by ULTRATEK HRP (Scy Tek Laboratories, UT, USA) for CD31 and by Bond Polymer Refine Detection in an automated stainer (Leica Biosystem, Milan, Italy) for NFκB.

**Correlation study**

A collection of 174 RNA-Seq data samples from patients diagnosed with glioblastoma multiforme was retrieved from the Cancer Genome Atlas (TCGA). The data were produced by the University of North Carolina Cancer Genomic Characterization Center (CGCC) using the Illumina HiSeq 2000 platform, and made available in TCGA as Level 3 (preprocessed) data. The TCGA data were retrieved from the Genomic Data Commons (GDC) using the following search query:

Disease Type IS Glioblastoma Multiforme AND Primary Site IS Brain AND Program Name IS TCGA AND Project Id IS TCGA-GBM AND Access IS open AND Data Category IS Gene expression AND Data Format IS TXT AND Data Type IS Gene expression quantification AND Experimental Strategy IS RNA-Seq AND Platform IS Illumina HiSeq

Among the files retrieved by this query, we employed the files reporting RSEM normalized gene expression. More details on how to retrieve these data are provided in the Supplementary Materials (Supplementary file 1). Data processing was carried out using the SeqWare Pipeline project’s MapspliceRSEM workflow (version 0.7) (O’Connor et al., 2010). Gene-level expression data were estimated using RSEM (Li and Dewey, 2011) and normalized to set the upper quartile count at 1,000 for gene level. Correlation between gene expression profiles in the 174 samples was computed as the Pearson product-moment correlation coefficient, setting the p-value threshold at 0.01.

**Survival analysis on high-grade glioma patients**

Microarray gene expression data, obtained using the Affymetrix U133A chip on a set of 77 high-grade gliomas (Phillips et al., 2006) and for which patient follow-up was available, were retrieved from the Gene Expression Omnibus (GEO series Id GSE4271) in the form of MAS5-normalized intensities. The distribution of Caspase-8 expression was divided in three equal-size quantiles; patients whose Caspase-8 expression was in the first quantile were classified as ‘Low Expression’, while those whose Caspase-8 expression was in the third quantile were classified as ‘High Expression’. Patient stratification depending on Caspase-8 expression was computed for all patients together, and also independently for the three subtypes in which the patients were classified (proneural, mesenchymal or proliferative). Survival curves and the Kaplan-Meier estimator were computed and plotted using the R package survival (https://cran.r-project.org/web/packages/survival/index.html).

**Acknowledgements**

We thank, D Stupack, Y Ciribilli, A Inga, for kindly providing reagents, V Stagni and F Moretti for critical reading of the manuscript and Gerry Melino for helpful discussion. This work has been supported by research grants from AIRC (IG1408, IG10590, n.19069), AICR (AICR 07–0461) and PRIN 2010_M4NEFY_005 to DB, and from AIRC (n. 18560) to DDB. MPM was supported by a fellowship provided by PNR-CNR Progetto Invecchiamento to AL.
Additional information

**Funding**

| Funder                                      | Grant reference number | Author                                    |
|---------------------------------------------|------------------------|-------------------------------------------|
| Consiglio Nazionale delle Ricerche          | PNR-CNR Progetto Invecchiamento | Maria Patrizia Mongiardi Andrea Levi     |
| Associazione Italiana per la Ricerca sul Cancro | n. 18560              | Donatella Del Bufalo                      |
| Associazione Italiana per la Ricerca sul Cancro | IG1408                | Daniela Barilà                            |
| Ministero dell’Istruzione, dell’Università e della Ricerca | PRIN 2010_M4NEFY_005 | Daniela Barilà                            |
| Worldwide Cancer Research                   | AICR 07-0461           | Daniela Barilà                            |
| Associazione Italiana per la Ricerca sul Cancro | n.19069              | Daniela Barilà                            |
| Associazione Italiana per la Ricerca sul Cancro | IG10590              | Daniela Barilà                            |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Author contributions**

GF, Designed and performed the cell biology and biochemical experiments, contributed to project conceptualization and co-wrote and edited the paper, Read and approved the final version of the paper; MPM, Contributed to Quantitative Real Time Experiments, and co-wrote and edited the paper, Read and approved the final version of the paper; AL, Contributed to project conceptualization, provided funding through competitively awarded grants to support MPM and co-wrote the paper, Read and approved the final version of the paper; TDL, Performed the neo-angiogenesis experiments in mice and their data analysis, Read and approved the final version of the paper; MD, Performed the in vivo tumorigenesis experiments (mouse xenograft experiments in mice) and their data analysis, Read and approved the final version of the paper; DT, Performed the in vitro angiogenesis experiments and their data analysis, Read and approved the final version of the paper; DDB, Provided funding through competitively awarded grants, coordinated the angiogenesis experiments and co-wrote the paper, Read and approved the final version of the paper; IC, Set-up and performed the immunofluorescence experiments and their data analysis, Read and approved the final version of the paper; ADB, Set-up and performed the immunohistochemistry experiments on tumor samples and their data analysis, Read and approved the final version of the paper; MM, Supervisioned and performed the immunohistochemistry experiments on tumor samples and their data analysis, Read and approved the final version of the paper; AG, Supervisioned the cytokine detection by Luminex Technology experiments and their data analysis, Read and approved the final version of the paper; DC, Supervisioned the cytokine detection by Luminex Technology experiments and their data analysis, Read and approved the final version of the paper; FF, Performed all the bioinformatic analysis and co-wrote the paper, Read and approved the final version of the paper; DB, Conceived the project, provided funding through competitively awarded grants, coordinated the project, supervisioned all the experiemnts and data analysis and wrote the paper, Read and approved the final version of the paper

**Author ORCIDs**

Fabrizio Ferre, [http://orcid.org/0000-0003-2768-5305](http://orcid.org/0000-0003-2768-5305)
Daniela Barilà, [http://orcid.org/0000-0002-6192-1562](http://orcid.org/0000-0002-6192-1562)

**Ethics**

All procedures involving animals and their care were authorized and certified by the decree n.26/2014 of the Italian Minister of Health following the relative guide lines
# Additional files

**Supplementary files**
- Supplementary file 1. The Cancer Genome Atlas data retrieval. DOI: 10.7554/eLife.22593.027

**Major datasets**
The following previously published datasets were used:

| Author(s) | Year | Dataset title | Dataset URL |
|-----------|------|---------------|-------------|
| Bisio A, Albulescu R, San Z, Feuerstein B, Williams PM, Modrusan Z, Feuerstein B, Aldape K | 2013 | Molecular subclasses of high-grade glioma: prognosis, disease progression, and neurogenesis | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE4271 |
| Fianco G, Niccolini E, Ferri CR, Lanzavecchia A, Brolli G, Fumagalli S, Baroni M, Viale A, Fanti F, Valsecchi M, Viale G, Altieri DC, Tosi P, Alberti E, Ascone P, Rotmensz N, Scarpa A | 2014 | BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. | doi: 10.1038/carcin/bgt242 |

**References**

Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP. 2013. Cytokine patterns in brain tumour progression. *Mediators of Inflammation* **2013**:979748. doi: 10.1155/2013/979748, PMID: 23864770

Ando M, Kawazu M, Ueno T, Fukumura K, Yamato A, Soda M, Yamashita Y, Choi YL, Yamashoba T, Mano H. 2013. Cancer-associated missense mutations of caspase-8 activate nuclear factor-xB signaling. *Cancer Science* **104**:1002–1008. doi: 10.1111/cas.12191, PMID: 23659359

Bidère N, Snow AL, Sakai K, Zheng L, Lenardo MJ. 2006. Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation. *Current Biology* **16**:1666–1671. doi: 10.1010/j.cub.2006.06.062, PMID: 16920630

Bisio A, Žamborszky J, Zaccara S, Lion M, Tebaldi T, Sharma V, Raimondi I, Alessandrini F, Ciribilli Y, Inga A. 2014. Cooperative interactions between p53 and NFkappaB enhance cell plasticity. *Oncotarget* **5**:12111–12125. doi: 10.18632/oncotarget.2545, PMID: 25401416

Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK, Furnari FB. 2012. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. *Oncogene* **31**:4054–4066. doi: 10.1038/onc.2011.563, PMID: 22139077

Breckman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. 1995. Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappaB activation. *Molecular and Cellular Biology* **15**:2809–2818. doi: 10.1128/MCB.15.5.2809, PMID: 7739562

Cahill KE, Morshed RA, Yamini B. 2016. Nuclear factor-kB in glioblastoma: insights into regulators and targeted therapy. *Neuro-Oncology* **18**:329–339. doi: 10.1093/neuonc/nox265, PMID: 26534766

Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A, Bonifazi AP, Coppola L, Superti-Furga G, Testi R, Barilla D. 2016. Caspase-8 expression and its Src-dependent phosphorylation on Tyr380 promoted Cancer cell neoplastic transformation and resistance to anoikis. *Experimental Cell Research* **347**:114–122. doi: 10.1016/j.yexcr.2016.07.013, PMID: 27432652

Gabellini C, De Luca T, Trisciuglio D, Desideri M, Di Martile M, Passeri D, Candilor A, Biffoni M, Rizzo MG, Orlandi A, Del Bufalo D, Luca, t DE, Martile, m DI, Bufalo, D DEL. 2006. Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. *The EMBO Journal* **25**:1895–1905. doi: 10.1038/sj.emboj.7601085, PMID: 16619028

Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle K, Agarwalla PK, Ghedda MG, Campos B, Wang A, Brennan C, Ligon K, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes & Development* **26**:756–784. doi: 10.1101/gad.187922.112, PMID: 22508724

Fianco G, Cenci C, Barilà D. 2016. Caspase-8 expression and its Src-dependent phosphorylation on Tyr380 promote Cancer cell neoplastic transformation and resistance to anoikis. *Experimental Cell Research* **347**:114–122. doi: 10.1016/j.yexcr.2016.07.013, PMID: 27432652

Gabellini C, De Luca T, Trisciuglio D, Desideri M, Di Martile M, Passeri D, Candilor A, Biffoni M, Rizzo MG, Orlandi A, Del Bufalo D, Luca, t DE, Martile, m DI, Bufalo, D DEL. 2013. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. *Carcinogenesis* **34**:2558–2567. doi: 10.1093/carcin/bgt242, PMID: 23836782

Graf RP, Keller N, Barbero S, Stupack D. 2014. Caspase-8 as a regulator of tumor cell motility. *Current Molecular Medicine* **14**:246–254. doi: 10.2174/156554201466614012111951, PMID: 24467204

Hanahan D, Weinberg RA. 2011. Hallmarks of Cancer: the next generation. *Cell* **144**:646–674. doi: 10.1016/j.cell.2011.02.013, PMID: 21376230

Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, Tan P, Depinho RA, Cavenee W, Furnari F. 2010. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. *Genes & Development* **24**:1731–1745. doi: 10.1101/gad.1890510, PMID: 20713517
Juo P, Kuo CJ, Yuan J, Blenis J. 1998. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Current Biology 8:1001–1008. doi: 10.1016/S0960-9822(07)00420-4, PMID: 9740801

Kargiotis O, Rao JS, Kyritsis AP. 2006. Mechanisms of angiogenesis in gliomas. Journal of Neuro-Oncology 78:281–293. doi: 10.1007/s11060-005-9097-6, PMID: 16554966

Karin M, Cao Y, Greten FR, Li ZW. 2002. NF-kappaB in Cancer: from innocent bystander to Major culprit. Nature Reviews Cancer 2:301–310. doi: 10.1038/nrc780, PMID: 12001991

Khalifian S, Raimondi G, Brandacher G. 2015. The use of luminex assays to measure cytokines. Journal of Investigative Dermatology 135:1–5. doi: 10.1038/jid.2015.36, PMID: 25785953

Lemmers B, Salmena L, Bidere N, Su H, Matysiak-Zablocki E, Murakami K, Ohashi PS, Jurisicova A, Lenardo M, Hakem R, Hakem A. 2007. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. Journal of Biological Chemistry 282:7416–7423. doi: 10.1074/jbc.M606721200, PMID: 17213198

Li B, Dewey CN. 2011. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. doi: 10.1186/1471-2105-12-323, PMID: 21816040

Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436–444. doi: 10.1038/20070205, PMID: 18650914

Nogueira L, Ruiz-Onatgon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL. 2011. The nfbcl pathway: a therapeutic target in glioblastoma. Oncotarget 2:646–653. doi: 10.18632/oncotarget.322, PMID: 21896960

O’Connor BD, Merriman B, Nelson SF. 2010. SeqWare Query Engine: storing and searching sequence data in the cloud. BMC Bioinformatics 11 Suppl 12:S2. doi: 10.1186/1471-2105-11-S12-S2, PMID: 21210981

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soracezuelo L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173. doi: 10.1016/j.ccr.2006.02.019, PMID: 16530701

Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, Shalaby T, Grotzer MA. 2003. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 9:6401–6409. PMID: 14695141

Safa AR, Day TW, Wu CH. 2008. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for Cancer therapy. Current Cancer Drug Targets 8:37–46. doi: 10.2174/156800908783497087, PMID: 18288942

Scharner D, Rossig L, Carmona G, Chavakis E, Urbich C, Fischer A, Kang TB, Wallach D, Chiang YJ, Deribe YL, Dikic I, Zeiher AM, Dimmeler S. 2009. Caspase-8 is involved in neovascularization-promoting progenitor cell functions. Arteriosclerosis, Thrombosis, and Vascular Biology 29:571–578. doi: 10.1161/ATVBAHA.108.182006, PMID: 19122169

Stagni V, Manni I, Oropallo V, Mottolese M, Di Benedetto A, Piaggio G, Falconi R, Giaccari D, Di Carlo S, Sperati F, Canuto R, Falcioni R, Giaccari D, Di Carlo S, Orofino V, Cencioni MT, Barila D. 2015. ATM kinase sustains HER2 tumorigenicity in breast cancer. Journal of Biological Chemistry 290:28180–28191. doi: 10.1074/jbc.M114.590303, PMID: 26056341

Stupack DG. 2013. Caspase-8 as a therapeutic target in Cancer. Cancer Letters 332:133–140. doi: 10.1016/j.canlet.2010.07.022, PMID: 20817393

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curtzman J, Janzer RC, Ludwig SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer EP, Mandoni D, Reardon DA, DeAngelis LM. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352:977–986. doi: 10.1056/NEJMoa043330, PMID: 15758009

Su H, Bidere N, Zheng L, Cubre A, Sakai K, Dale J, Salmena L, Hakem R, Straus S, Lenardo M. 2005. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 307:1465–1468. doi: 10.1126/science.1104765, PMID: 15746428

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi: 10.1016/j.ccr.2009.12.020, PMID: 20129251

Yeung YT, McDonald KL, Grewal T, Munoz L. 2013. Interleukins in glioblastoma pathophysiology: implications for Cancer therapy. British Journal of Pharmacology 168:591–606. doi: 10.1111/bph.12008, PMID: 23062197